Innovative Medicine

Innovative Medicine

February 12, 2013

Follow-up Data Show ZYTIGA® Plus Prednisone Continues to Delay Progression of Metastatic Castration-Resistant Prostate Cancer in Patients without Prior Chemotherapy

Innovative Medicine

February 5, 2013

XARELTO® to be Studied with Factor Xa Inhibitor Antidote

Janssen and Bayer Announce Clinical Collaboration Agreement with Portola

Innovative Medicine

January 11, 2013

ZYTIGA® Approved In The EU For Use In The Treatment Of Metastatic Castration-Resistant Prostate Cancer Before Chemotherapy

Innovative Medicine

January 10, 2013

FDA Advisory Committee Recommends Approval of Canagliflozin for Treatment of Adults with Type 2 Diabetes

Innovative Medicine

December 31, 2012

FDA Grants Accelerated Approval for SIRTURO™ (bedaquiline) as Part of Combination Therapy to Treat Adults with Pulmonary Multi-Drug Resistant Tuberculosis

Innovative Medicine

December 27, 2012

New Category I CPT Codes and Payment Rates for Circulating Tumor Cell Testing Effective January 1

New codes granted in recognition of clinical efficacy

Innovative Medicine

December 12, 2012

The New England Journal of Medicine Publishes Efficacy Data for ZYTIGA® Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer in Patients Who Have Not Received Chemotherapy

Data Supports This Week’s FDA Approval

Innovative Medicine

December 12, 2012

CellSearch® ‘Liquid Biopsy’ Approved for Breast Cancer Patients in China

Research

December 12, 2012

Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin/Metformin Fixed-Dose Combination Therapy to Treat Patients with Type 2 Diabetes